BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Allozyne, Inc. 

1600 Fairview Ave E.
Suite 300
Seattle  Washington  98102  U.S.A.
Phone: 206-518-5700 Fax: 206-518-5799


SEARCH JOBS




Industry
Biotechnology

Segment
Biotechnology





 Company News
Allozyne, Inc. Sold For Scrap As MedImmune (AZN) Snaps Up Rights 9/19/2014 6:50:12 AM
Allozyne, Inc. Conducts Round of Employee "Furloughs" 3/15/2013 12:17:09 PM
Poniard Pharmaceuticals, Inc. (PARD) Announces Shareholders Approve Merger With Allozyne, Inc. 11/22/2011 7:39:44 AM
Allozyne, Inc. Announces Positive Results from Phase 1B Trial of AZ01 10/19/2011 7:01:59 AM
Poniard Pharmaceuticals, Inc. (PARD) Announces Effectiveness of Form S-4 Registration Statement for the Proposed Merger with Allozyne, Inc. 10/10/2011 9:16:49 AM
Poniard Pharmaceuticals, Inc. (PARD) Announces Filing of Form S-4 Registration Statement Related to Proposed Merger With Allozyne, Inc. 7/26/2011 9:01:39 AM
Allozyne, Inc. Acquires Poniard Pharmaceuticals, Inc. (PARD), Finds Backdoor Route to NASDAQ 6/23/2011 8:21:49 AM
Allozyne, Inc. Announces Completion of Phase IA Trial by AZ01, a Long Lasting Interferon B for Treatment of Relapsing Remitting Multiple Sclerosis 1/11/2011 9:31:01 AM
Allozyne, Inc. Announces Completion of Phase Ia Trial By Az01, a Long Lasting Interferon ? for Treatment of Relapsing Remitting Multiple Sclerosis 1/10/2011 12:08:00 PM
Allozyne, Inc. Announces Positive Proof of Concept Data For Az17, a Bispecific Th17 Antagonist for Treatment of Autoimmune Diseases 11/16/2010 12:55:50 PM
12